Chi-Med to Announce 2020 Final Results

On February 3, 2021 Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) reported that it will be announcing its final results for the year ended December 31, 2020 on Thursday, March 4, 2021 at 12:00 noon Greenwich Mean Time (GMT) / 8:00 pm Hong Kong Time (HKT) / 7:00 am Eastern Standard Time (EST) (Press release, Hutchison China MediTech, FEB 3, 2021, https://www.chi-med.com/chi-med-to-announce-2020-final-results/ [SID1234574531]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by Chi-Med management.

The conference call and audio webcast will take place at 1:00 pm GMT / 9:00 pm HKT / 8:00 am EST on Thursday, March 4, 2021 and will be webcast live via the company website at www.chi-med.com/investors/event-information/. The presentation will be available for downloading before the conference call begins. Details of the conference call dial-in will be provided in the financial results announcement and on the company website. A replay will also be available on the website shortly after the event.

Innate Pharma to host key opinion leader discussion on the potential role of lacutamab across T-cell lymphomas

On February 3, 2021 Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) ("Innate" or the "Company") reported that it will host a virtual key opinion leader (KOL) discussion focused on the potential role of its lead investigational drug candidate, lacutamab, an anti-KIR3DL2 cytotoxicity-inducing antibody in development for T-cell lymphomas (Press release, Innate Pharma, FEB 3, 2021, View Source [SID1234574530]). The event will be held virtually on Tuesday, February 9, 2021 at 2:00 p.m. CET / 8:00 a.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The event will feature presentations from the Company’s executive leadership team, as well as the following KOLs:

Pierluigi Porcu, M.D., Professor of Medical Oncology, Dermatology and Cutaneous Biology and Director, Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation at Thomas Jefferson University, US; Principal Investigator of Innate’s Phase 2 TELLOMAK clinical trial, which is evaluating lacutamab in mycosis fungoides and Sézary syndrome; and
Olivier Hermine, M.D., Professor of Hematology at the University of Paris Descartes and Director, Division of Adult Hematology at Hôpital Universitaire Necker Enfants Malades, Member of the Académie des Sciences, Member of the Lymphoma Study Association (LYSA), France
Presenters will provide an overview of the treatment landscape and prevalence of the lacutamab target, KIR3DL2, across subtypes of T-cell lymphoma. They will also highlight the potential impact of lacutamab in current and upcoming clinical programs in cutaneous and peripheral T-cell lymphomas.

Details for the Virtual Event

The live webcast of the event will be available at the following link:
View Source

A telephone number will also be made available. Participants may register in advance of the event at View Source Upon registration, participants will be provided with dial-in numbers, a direct event passcode and a unique registrant ID that they may use 10 minutes prior to the event start to access the call. Call reminders will also be sent to registered participants via e-mail the day prior to the event.

A replay of the webcast will be archived on Innate’s website for 90 days following the event.

This information can also be found in the Investors section of the Innate website, www.innate-pharma.com.

About Lacutamab:
Lacutamab (IPH4102) is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is currently in clinical trials for treatment of cutaneous T-cell lymphoma (CTCL), an orphan disease. This group of rare cutaneous lymphomas of T lymphocytes has a poor prognosis with few efficacious and safe therapeutic options at advanced stages.

KIR3DL2 is an inhibitory receptor of the KIR family, expressed by approximately 65% of patients across all CTCL subtypes and expressed by up 90% of patients with certain aggressive CTCL subtypes, in particular, Sézary syndrome. It is expressed by up to 50% of patients with peripheral t-cell lymphoma (PTCL). It has a restricted expression on normal tissues.

MAIA Biotechnology, Inc. Announces Clinical Supply Agreement with Regeneron for Phase 1/2 Clinical Trial Evaluating THIO in Sequential Administration with Libtayo® (cemiplimab) in Advanced Non-Small Cell Lung Cancer

MAIA Biotechnology, Inc., a targeted therapy, immuno-oncology company focused on development of first-in-class oncology drugs, reported that a clinical supply agreement with Regeneron Pharmaceuticals, Inc. (REGN) to evaluate THIO (aka 6-thio-dG) followed by the PD-1 inhibitor Libtayo (cemiplimab), in a Phase 1/2 clinical trial in second-line or later advanced non-small cell lung cancer (NSCLC) patients who have progressed following treatment with standard-of-care regimen that includes a checkpoint inhibitor. This clinical trial will evaluate the safety and efficacy of four dose levels of THIO, the only telomere-by-telomerase targeting agent in development for the treatment of cancer, followed by Libtayo. The lead-in portion of the study will initially assess the safety and immunogenic effects of each of the THIO doses and overall response rate (ORR) as the basis for potentially expanding individual patient cohorts and evaluation in other cancer types. The Phase 1/2 clinical trial is expected to begin enrolling patients in 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

We are excited for the opportunity to partner with Regeneron on our planned clinical trial of THIO and believe this collaboration to be validating of the program’s potential to transform both the immuno-oncology landscape and the cancer treatment paradigm," stated Vlad Vitoc, MD, MAIA’s Chief Executive Officer and President. "Notably, THIO has a well-demonstrated clinical safety profile at varying dosage levels and in preclinical results, low-dose THIO followed by immunotherapy has shown complete elimination of advanced tumors with no indication of treatment limiting toxicity. The efficacy results of this trial are expected to support the continued development of THIO in NSCLC and potentially its expansion to treat a vast array of other cancers. Based on our extensive preclinical experience, we believe that THIO may transform immunologically ‘cold’ tumors into ‘hot’, rendering them responsive to standard-of-care immuno-oncology therapies, and potentially improving their effectiveness."

Under the terms of the collaboration, MAIA will sponsor and fund the planned clinical trial and Regeneron will provide Libtayo. MAIA maintains global development and commercial rights to THIO and is free to develop the program in combination with other agents outside of NSCLC.

"At Regeneron, we seek opportunities to explore cutting-edge approaches to cancer treatment with other healthcare innovators who have complementary expertise," said Israel Lowy, M.D., Ph.D., Senior Vice President, Translational and Clinical Sciences, Oncology, at Regeneron. "Priming tumors with THIO before Libtayo treatment is a novel approach that may enhance and extend the potential benefits of immunotherapy for patients with advanced non-small cell lung cancer, and we look forward to seeing if the positive pre-clinical results that MAIA has published will translate to the clinic."

THIO followed by Libtayo for the treatment of advanced non-small cell lung cancer is currently under clinical development, and the safety and efficacy of THIO or its administration with Libtayo have not be reviewed by any regulatory authorities. Libtayo is being jointly developed by Regeneron and Sanofi. MM Dillon & Co. acted as advisors to MAIA Biotechnology, Inc.

About the Phase 1/2 Clinical Trial

This trial will be the first to test THIO’s immune system activation followed by administration of the checkpoint inhibitor Libtayo, allowing for the immune activation and PD-1 sensitivity to take effect. The trial will test the hypothesis that lower doses of THIO administered prior to Libtayo treatment would enhance and prolong responses in subjects with advanced NSCLC who did not respond or progressed after first-line treatment with a checkpoint inhibitor.

The initial part of the trial will assess both the safety, mechanistic activity and immune system activation of four THIO dose levels, each in separate arms. Each dosing arm will then be evaluated further for efficacy based on Overall Response Rate (ORR), Duration of Response (DoR), Progression Free Survival (PFS) and Overall Survival (OS). Additional patients may be recruited for further clinical evaluation in any of the THIO arm(s) based on safety and clinical benefit. A total of up to 40 evaluable patients will be enrolled in each of the arms of the trial.

About Non-small Cell Lung Cancer

Lung cancer is the leading cause of cancer death worldwide, In 2020, more than 2.2 million and 228,000 new cases were estimated to have been diagnosed globally and in the U.S., respectively. Approximately 85% of all lung cancers are NSCLC, and an estimated 80% of these cases are telomerase positive [TERT(+)]. While immunotherapies have transformed advanced NSCLC treatment in recent years, there remains a significant unmet need to optimize treatment of patients and offer additional clinical options.

About THIO

THIO (aka 6-thio-dG, 6-thio-2’-deoxyguanosine) is a first-in-class small molecule that is the only telomere-by-telomerase targeting agent currently in development. THIO selectively kills cancer cells by modifying telomeric DNA structure and function utilizing telomerase. Telomerase is present in >85% of human cancers and contributes significantly to the proliferation and reproductive immortality of cancer cells. THIO’s activity was shown to be cancer-specific in tumor types with active telomerase. THIO is recognized by telomerase and incorporated into telomeres selectively in cancer cells. Once incorporated, it compromises the telomere structure and function, leading to ‘uncapping’ of the chromosome ends and thus resulting in rapid tumor cell death. Low doses of THIO, followed by anti-PD-L1 or anti-PD1 therapy, completely eliminated advanced tumors in preclinical models and produced cancer cell specific immune memory, where the immune system continued to be active against the cancer cells after extended periods of time, with no additional treatment. These results demonstrate how the THIO-produced telomere stress increases innate sensing and adaptive anti-tumor immunity, which provides a strong rationale for sequentially combining telomere-targeted therapy with immunotherapy. THIO is investigational and has not been approved for any use by regulatory authorities.

Xylyx Bio and Cell&Soft Announce positive initial results following Strategic Partnership to Develop Next-Generation in vitro Platforms to Accelerate Cancer Drug Discovery

On February 2, 2021 Xylyx Bio, a leader in predictive disease models and tissue-specific extracellular matrix (ECM) products, and Cell&Soft SAS, a French biotech company specializing in innovative soft cell culture plates, reported positive preliminary results, reaching a key milestone in their partnership to develop more physiologically relevant in vitro cellular models for cell-based assays in oncology (Press release, Xylyx Bio, FEB 2, 2021, View Source [SID1234574517]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Existing in vitro models lack physiological relevance, yielding misleading and non-translatable results that slow essential progress needed to develop effective drugs capable of preventing thousands of cancer deaths each year.

The collaboration initially focuses on the development of products for lung adenocarcinoma. The promising early results indicated that the combination of Xylyx Bio lung-specific ECM surface coatings and Cell&Soft soft cell culture plates are compatible technologies and that lung tumor cells are highly functional in this environment. The resulting lung-specific soft cell culture products will enable scientists to develop more physiologically relevant pre-clinical tumor models to substantially improve the identification and selection of effective lung cancer therapies.

Camille Migdal, Ph.D., President and Co-Founder of Cell&Soft, said, "We are excited about combining our soft cell culture plates mimicking lung rigidity with Xylyx Bio lung-specific extracellular matrix. It opens a way towards innovative and relevant products for pulmonary in vitro cell culture."

Andrea Nye, President & CEO of Xylyx Bio, explained, "Collaborative relationships with innovative companies like Cell&Soft support the creation of improved tools that enable researchers to better model disease biology and increase predictability of drug efficacy, helping shift the overall paradigm from entrenched, non-predictive in vitro models to more accurate and actionable drug discovery."

Ascentage Pharma Released Preclinical Results of MDM2-p53 Inhibitor APG-115 in an Oral Presentation at WCLC 2020, Demonstrating Therapeutic Potential in STK11-Mutant Non-Small Cell Lung Cancer

On February 2, 2021 Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, reported that the company recently released the results from a preclinical study of APG-115, a novel MDM2-p53 inhibitor being developed by Ascentage Pharma, in the treatment of non-small cell lung cancer (NSCLC) harboring STK11 mutations through an oral presentation on January 29, 2021, at the 2020 World Conference on Lung Cancer (WCLC 2020) (Press release, Ascentage Pharma, FEB 2, 2021, View Source [SID1234574516]). The presentation was delivered by Dr. Hao Sun, from Guangdong Provincial People’s Hospital and Dr. Yilong Wu’s research team at Guangdong Lung Cancer Research Institute.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The World Conference on Lung Cancer, organized by the International Association for the Study of Lung Cancer (IASLC), is the world’s largest multidisciplinary scientific conference that focuses on the cutting-edge research and clinical advancements in the field of lung cancer and other thoracic malignancies.

APG-115 is an orally administered, selective, small-molecule inhibitor of the MDM2 protein. APG-115 has strong binding affinity to MDM2 and is designed to activate tumor suppression activity of p53 by blocking the MDM2-p53 protein-protein interaction. APG-115 is the first MDM2-p53 inhibitor entering clinical development in China, and is currently being investigated in multiple Phase Ib/II clinical studies in solid tumors and hematologic malignancies in China and the US.

The report presented by Dr. Sun was titled "MDM2 Inhibitor APG-115 Suppresses Cell Proliferation and Tumor Growth in Preclinical Models of NSCLC Harboring STK11 Mutations". Results from this study showed that APG-115 has therapeutic potential in NSCLC harboring STK11 mutations, and shows the potential of a new treatment option for the subgroup of patients with drug resistance to approved PD-1 inhibitors.

STK11/LKB1 and KRAS co-mutations represent one of the three common oncogenic subtypes of KRAS-mutant lung adenocarcinoma. STK11/LKB1 mutations affect the tumor immune microenvironment, and are associated with the reduction of invasive cytotoxic CD8+T-cells in both patient-derived xenograft (PDX) models and mouse models. STK11/LKB1 mutations are a main driver of drug resistance to PD-1 inhibitors in patients with KRAS-mutant lung adenocarcinoma, therefore could predict the poor prognosis of immunotherapy in these patients. In addition, STK11/LKB1 mutations also have implications on cysteine metabolism.

This study showed, compared to the wild-type cell line, the NSCLC cell line harboring STK11/LKB1 mutations was highly sensitive to APG-115. APG-115 achieved its antitumor effects by inducing ferroptosis in the cancer cells harboring STK11/LKB1 mutations. In the PDX models of STK1/LKB1-mutant NSCLC, APG-115 as a single agent displayed potent antitumor activities, achieving a response rate of 66% in PDX models harboring mutant STK11. These results suggest that STK11/LKB1 mutations may be used as a biomarker for potential treatment by MDM2 inhibitors, and APG-115 as a potential therapy for STK11/LKB1-mutant NSCLC and possibly a new treatment option for those patients with primary drug resistance to PD-1 inhibitors.

"There remains to be enormous unmet medical needs in the treatment of NSCLC, particularly with those patients harboring STK11 mutations who are resistant to immunotherapies and therefore lack effective treatment options," said Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma. "As the first MDM2-p53 inhibitor entering clinical development in China, APG-115 is currently being investigated in multiple Phase Ib/II clinical studies. Those results reported at WCLC 2020 have demonstrated APG-115’s therapeutic potential in STK11-mutant NSCLC, and provided additional scientific basis warranting the future clinical investigation of the drug candidate in patients with NSCLC, in particular, those with primary drug resistance to PD-1 inhibitors. We will accelerate the clinical development of APG-115 and strive to bring a novel therapeutic to patients in need."